Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01692223 · ClinicalTrials.gov registry record

A Safety Study Assessing the Effects of Receiving Genome Sequencing Results

A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
8
Enrollment target

NCT01692223: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01692223 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01692223 has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
8 participants
Enrollment target

Study Summary

This study uses new methods called "genome sequencing" that allow the investigators to study part or all of a person's genome. The genome is the collection of all of a person's genes. Genes carry the instructions that our bodies need to develop and function. Genes are passed on from one generation to the next. Genome sequencing can study all of a person's genome (whole genome sequencing) or just parts of their genome (whole exome sequencing). In the study, the investigators refer to all these research methods as 'genome sequencing'. Genome sequencing typically shows a large number of gene changes, known as "variants." Some (but not all) of these genetic variants may be linked to increased risks of diseases other than cancer. The purpose of this study is to learn what kinds of genetic variants the patient wants to learn about from their genome.

Primary Outcome

of receiving incidentally identified disease risk results from whole genome/exome sequencing. Safety is defined as no more than 20% of participants experiencing clinically meaningful levels of distress at 1 week follow-up, as measured by the Hospital Anxiety \& Depression Scale (HADS; score \> or = to 8 on the anxiety sub-scale). Patients will be considered evaluable for the primary outcome if they are not distressed at baseline and have completed the 1 week follow-up assessment.

Interventions

  • BEHAVIORAL qualitative interviews

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2012-09
Est. Completion 2018-08
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT01692223 record still lists

NCT01692223 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which qualitative interviews is the first listed.

NCT01692223 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01692223 about?

NCT01692223 is a clinical study titled "A Safety Study Assessing the Effects of Receiving Genome Sequencing Results". This study uses new methods called "genome sequencing" that allow the investigators to study part or all of a person's genome. The genome is the collection of all of a person's genes. Genes carry the instructions that our bodies need to develop and function. Genes are passed on from one generation t...

What is the current status of trial NCT01692223?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-09. Estimated completion is 2018-08.

What interventions are being tested in trial NCT01692223?

The interventions under investigation include: qualitative interviews (BEHAVIORAL).

Who is sponsoring clinical trial NCT01692223?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01692223, the US trial registry maintained by the National Library of Medicine. NCT01692223 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.